Women's Health
What Causes Low Mood in Menopause?
Low mood affects up to 40% of women during the menopausal transition — yet it's frequently dismissed or misdiagnosed as clinical depression. Understanding the hormonal, neurochemical, and nutritional drivers behind it is the first step toward targeted relief that actually works.
What Causes Low Mood in Menopause?
For most women, yes — low mood during menopause is real, hormonally driven, and distinct from a primary depressive disorder. Falling estrogen disrupts serotonin and dopamine signaling, progesterone loss reduces GABA activity, and cortisol dysregulation compounds both. The important caveat: nutrient deficiencies (especially vitamin D, magnesium, and B vitamins) often amplify the mood dip significantly, meaning targeted repletion can move the needle even when hormones are the root cause.
---
The Hormonal Architecture of Menopausal Mood
Estrogen does far more than regulate the reproductive cycle. It acts as a neuromodulator — upregulating serotonin receptors, increasing tryptophan availability, and supporting dopamine synthesis in the prefrontal cortex. When estradiol declines during perimenopause, all three pathways weaken simultaneously.
A landmark review published in Maturitas found that women in the menopausal transition have roughly twice the risk of developing depressive symptoms compared with premenopausal women, and that this risk is most pronounced during the period of greatest hormonal variability — not at the point of lowest estrogen (Cohen et al., Maturitas 2006; PMID: 16406383).
Progesterone adds another layer. Its primary metabolite, allopregnanolone, is a potent positive allosteric modulator of GABA-A receptors — the same receptors targeted by benzodiazepines. As progesterone falls in perimenopause, GABA tone drops, anxiety rises, sleep degrades, and mood follows. This is part of why low mood in the menopausal transition so often presents with a mixed anxiety-depression picture rather than pure sadness.
Cortisol further complicates the picture. HPA axis dysregulation is common during midlife — both from the hormonal transition itself and from accumulated life stress — and chronically elevated cortisol suppresses hippocampal neurogenesis and serotonin receptor sensitivity. For practical context on mood swings and irritability driven by hormonal and nutritional root causes, the interplay between cortisol and sex hormones is a recurring theme.
---
What Causes Low Mood in Early Menopause?
Early menopause — whether natural or induced — creates a particularly steep hormonal gradient because the decline happens over a compressed time window rather than the gradual years-long transition seen in average-onset menopause. The brain's neuroadaptive capacity is outpaced by the speed of the drop.
Research from the Study of Women's Health Across the Nation (SWAN) cohort — one of the largest longitudinal studies of menopausal transition — found that the perimenopause phase itself, characterized by erratic estrogen fluctuations rather than simply low estrogen, predicted depression symptoms more strongly than any other menopausal stage (Bromberger et al., Archives of General Psychiatry 2011; PMID: 21969460). The takeaway: it's hormonal volatility, not just hormonal loss, that drives mood instability in early menopause.
Nutritionally, early menopause often coincides with declining vitamin D status. Vitamin D receptors are expressed throughout the limbic system, and low serum 25(OH)D is consistently associated with depressive symptom severity in perimenopausal cohorts. If you're tracking your own labs, low vitamin D symptoms, causes, and lab markers is a useful reference for understanding what optimal looks like beyond just avoiding deficiency.
B vitamins — particularly B6, B9 (folate), and B12 — are also critical here. They are rate-limiting cofactors for serotonin and dopamine synthesis via the methylation pathway. Suboptimal B12 or folate can look and feel identical to hormonally driven low mood, which is why a biomarker-first approach matters.
---
What Causes Low Mood in Surgical Menopause?
Surgical menopause — the abrupt cessation of ovarian function following bilateral oophorectomy — produces the most severe and rapid hormonal decline of any menopausal scenario. Estradiol and testosterone drop to near-zero within 24–48 hours of surgery, a change that would take years in natural menopause.
The mood consequences are proportionally acute. A Mayo Clinic cohort study found that women who underwent bilateral oophorectomy before age 50 had a significantly elevated lifetime risk of depression and anxiety compared with age-matched women who underwent natural menopause (Rocca et al., Neurology 2008; PMID: 18776473). Crucially, hormone therapy initiated promptly after surgery attenuated — but did not fully eliminate — this elevated risk, suggesting both hormonal and non-hormonal mechanisms are at play.
Testosterone is often overlooked in surgical menopause discussions. The ovaries contribute approximately 50% of a woman's testosterone production; their removal produces a simultaneous testosterone deficit that compounds mood, motivation, and libido disruption. Low libido: the hormonal, nutritional, and stress drivers for men and women covers the testosterone-mood-libido axis in detail, and the mechanisms apply directly to post-surgical women.
For women who cannot or choose not to use hormonal therapy after surgical menopause, evidence-based adaptogen and nutritional strategies become especially important, though they should be discussed with a healthcare provider as a complement to — not a replacement for — medical management.
---
What Causes Low Mood in Women Coming Off the Pill?
Synthetic progestins in combined oral contraceptives suppress endogenous ovulation and, with it, the natural progesterone and testosterone production that typically follows ovulation. When women stop the pill, the transition back to endogenous hormonal cycling is rarely smooth.
Clinical data show that a subset of women experience a post-pill mood dip lasting weeks to months. A 2016 Danish registry study of over one million women found that hormonal contraceptive use was associated with subsequent antidepressant use and depression diagnosis, with adolescent users showing the strongest association (Skovlund et al., JAMA Psychiatry 2016; PMID: 27680324). While the study focused on pill use rather than discontinuation, the underlying mechanism — synthetic progestin effects on allopregnanolone and serotonin signaling — also explains the rebound dysregulation that can occur after stopping.
Nutritionally, long-term oral contraceptive use depletes several key micronutrients: B6, B12, folate, zinc, magnesium, and riboflavin. Mood symptoms emerging after pill cessation may therefore partly reflect these pre-existing depletions becoming symptomatic once the pharmacological progestin support is removed. Replenishing these nutrients systematically — ideally guided by lab results — often accelerates the mood recovery window considerably.
---
The Neuroinflammation Link
Beyond the classic serotonin narrative, emerging research points to neuroinflammation as a significant driver of menopausal low mood. Estrogen has anti-inflammatory effects in the central nervous system; its decline activates microglia and increases pro-inflammatory cytokine production in limbic regions. A 2020 review in Neuropsychopharmacology described how this neuroimmune shift can produce anhedonia, fatigue, and cognitive slowing through tryptophan diversion toward the kynurenine pathway rather than serotonin synthesis (Bromberger & Epperson, Neuropsychopharmacology 2018; PMID: 28952610).
This kynurenine diversion is particularly relevant because it means that simply adding tryptophan or 5-HTP without addressing inflammation may yield limited results. Omega-3 fatty acids (EPA in particular), vitamin D, and magnesium all have downstream anti-inflammatory effects in the CNS — and their combined insufficiency is strikingly common in midlife women.
---
Key Biomarkers Worth Testing
| Biomarker | Optimal Range | Why It Matters for Mood |
|---|---|---|
| Estradiol (E2) | Varies by phase; <20 pg/mL post-menopausal | Direct serotonin and dopamine modulation |
| Progesterone | >1 ng/mL (luteal phase) | GABA tone, sleep quality |
| Total testosterone | See age-based reference ranges | Motivation, anhedonia, libido |
| 25(OH) Vitamin D | 50–80 ng/mL | Limbic receptor expression, neuroinflammation |
| Serum magnesium (RBC) | 5.2–6.5 mg/dL | NMDA receptor regulation, cortisol buffering |
| hsCRP | <1 mg/L | Kynurenine pathway activation marker |
| Fasting insulin | <7 µIU/mL | Insulin resistance correlates with HPA dysregulation |
| Folate / B12 | B12 >400 pg/mL | Methylation cofactors for neurotransmitter synthesis |
Tracking these markers over time — not just at a single snapshot — gives the clearest picture of where the mood disruption is rooted. Patterns of high fasting insulin and insulin resistance, for instance, are increasingly recognized as contributing to menopausal mood instability through HPA axis crosstalk.
---
What This Means for Your Formula
Personalized supplementation during the menopausal transition should follow the biomarker picture, not a one-size-fits-all women's multi. That's the principle Ones is built on: the AI health practitioner analyzes your blood work, wearable data, and health history, then builds a custom capsule formula from a catalog of clinically validated ingredients.
For menopausal low mood specifically, three ingredients consistently emerge from the evidence base:
Ashwagandha (KSM-66, 600 mg/day): A randomized controlled trial in perimenopausal women found that KSM-66 ashwagandha root extract significantly improved scores on the Menopause-Specific Quality of Life questionnaire, including psychological symptoms, compared with placebo over 8 weeks (Gopal et al., Journal of Ethnopharmacology 2021; PMID: 33162192). The mechanism involves HPA axis modulation — cortisol reduction — which secondarily supports serotonin receptor sensitivity. Ones includes KSM-66 at the full clinical 600 mg dose when the formula warrants it.
Vitamin D3 + K2 (MK-7): When 25(OH)D is below 50 ng/mL — which describes the majority of midlife women in northern latitudes — supplementation has measurable effects on depressive symptom scores. The K2 pairing is included to direct calcium appropriately and avoid arterial calcification risk at higher D3 doses. Ones doses this combination based on your actual lab result, not a generic population assumption.
Omega-3 (EPA/DHA): EPA specifically has the strongest evidence base for mood support in inflammatory-driven depression. A meta-analysis of 19 clinical trials found EPA-dominant formulas superior to DHA-dominant or balanced formulas for depressive symptoms (Liao et al., Translational Psychiatry 2019; PMID: 31383846). Ones's Omega-3 inclusion targets the EPA:DHA ratio that aligns with your hsCRP and mood symptom profile.
Where the biomarkers and symptom picture also suggest adrenal involvement — common in perimenopause — Ones's proprietary Adrenal Support blend may be included alongside individual actives, addressing the cortisol-serotonin axis from multiple directions simultaneously.
---
Key Takeaways
- Low mood in menopause is primarily neurochemical, not psychological: Estrogen decline directly reduces serotonin and dopamine signaling; progesterone loss reduces GABA tone; both are biological, not character flaws.
- Hormonal volatility in early perimenopause drives mood instability more than estrogen nadir: The SWAN data show the transition phase — with erratic fluctuations — is the highest-risk period for depressive symptoms.
- Surgical menopause creates the most acute mood risk: Abrupt loss of both estrogen and testosterone demands prompt medical evaluation; adaptogens and nutrients are supportive adjuncts, not replacements for hormone therapy discussions.
- Post-pill mood dips are real and nutritionally mediated: OC use depletes B6, B12, folate, zinc, and magnesium — replenishing these systematically after cessation shortens recovery time.
- Neuroinflammation and the kynurenine pathway are underappreciated drivers: Omega-3 EPA, vitamin D, and magnesium address this mechanism where serotonin-targeted approaches alone may fall short.
- Biomarker-guided supplementation outperforms generic women's formulas: Testing estradiol, 25(OH)D, RBC magnesium, hsCRP, and B12 before building a protocol turns guesswork into precision — which is exactly what Ones is designed to do.
Always consult a qualified healthcare provider before starting, stopping, or changing any supplement protocol, particularly during hormonal transitions.